Theriva Biologics, Inc.
Symbol: TOVX (NYSE)
0.41
▲ (1.21%) 0.005
Company Description:
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Key Stats
- Today's Open: $0.399
- Today's High: $0.41
- Today's Low: $0.399
- Today's Volume: 44.47K
- Yesterday Close: $0.4051
- Yesterday High: $0.4051
- Yesterday Low: $0.387949
- Yesterday Volume: 167.21K
- Last Min Volume: 1.00K
- Last Min High: $0.41
- Last Min Low: $0.41
- Last Min VWAP: $0.41
Company Profile
- Name: Theriva Biologics, Inc.
- Website: https://www.therivabio.com
- Listed Date: 1993-04-05
- Location: ROCKVILLE, MD
- Market Status: Active
- CIK Number: 0000894158
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $3.89M
- Round Lot: 100
- Outstanding Shares: 9.60M
- Asset Type: CS
RECENT FILINGS FOR TOVX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-04 | 8-K | View |
| 2025-08-11 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-07-31 | SCHEDULE 13G | View |
| 2025-07-09 | ARS | View |
| 2025-07-09 | DEF 14A | View |
| 2025-06-25 | 8-K | View |
| 2025-06-20 | 8-K | View |
| 2025-06-20 | 424B5 | View |
| 2025-06-02 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-05-08 | 8-K | View |
| 2025-05-08 | 424B5 | View |
| 2025-05-07 | EFFECT | View |
| 2025-05-07 | 8-K | View |
| 2025-05-05 | CORRESP | View |
| 2025-05-05 | CORRESP | View |
| 2025-05-01 | 4 | View |
| 2025-05-01 | 4 | View |
Latest News on TOVX